Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Smallpox Vaccine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Smallpox Vaccine | BIOLOGICAL | - |
| HIVAC-1e | BIOLOGICAL | - |
| gp160 Vaccine (MicroGeneSys) | BIOLOGICAL | - |
Inclusion Criteria Concurrent Medication: Allowed: * All drugs, medications, and therapy which, by virtue of direct pharmacologic action or possible drug interaction, could influence the intended effects of the study vaccine or mask its side effects may be concomitantly administered only by presc...
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
The Smallpox (Vaccinia) Vaccine was studied in a Phase 1 clinical trial in people with HIV Infections. The trial compared it with HIVAC-1e in volunteers who had or had not been previously vaccinated against vaccinia. It is a vaccine modality in the infectious disease therapeutic area.
Bristol-Myers Squibb Company, which trades under the ticker BMY, is the developer associated with this Smallpox (Vaccinia) Vaccine program. The company sponsored the Phase 1 study evaluating the vaccine in HIV Infections.
The Smallpox (Vaccinia) Vaccine is in Phase 1 development for HIV Infections. One Phase 1 trial has been completed, and no active trials are ongoing. It is an investigational vaccine and is not described as approved for this use.
One trial, NCT00002261, titled a comparative Phase 1 clinical study of HIVAC-1e and Smallpox (Vaccinia) Vaccines, was conducted in the United States. It enrolled volunteers aged 18 years and older, including healthy volunteers, and the study has been completed.
The completed Phase 1 trial of the Smallpox (Vaccinia) Vaccine, NCT00002261, was an uncontrolled study and was not randomized or double blind. It compared HIVAC-1e and Smallpox (Vaccinia) Vaccines in previously vaccinated and unvaccinated volunteers.